The German Therapy Allergen Ordinance (TAO) triggered an ongoing upheaval in the market for house dust mite (HDM) allergen immunotherapy (AIT) products. Three HDM subcutaneous AIT (SCIT) products hold approval in Germany and therefore will be available after the scheduled completion of the TAO procedure in 2026. In general, data from clinical trials on the long-term effectiveness of HDM AIT are rare. We evaluated real-world data (RWD) in a retrospective, observational cohort study based on a longitudinal claims database including 60% of all German statutory healthcare prescriptions to show the long-term effectiveness of one of these products in daily life. Aim of this analysis was to provide a per product analysis on effectiveness of mite AIT as it is demanded by international guidelines on AIT.

中文翻译：

---

屋尘螨 SCIT 可降低哮喘风险并显着改善长期鼻炎和哮喘控制 — RWE 研究

德国过敏原治疗条例 (TAO) 引发了屋尘螨 (HDM) 过敏原免疫治疗 (AIT) 产品市场的持续剧变。三种 HDM 皮下 AIT (SCIT) 产品已在德国获得批准，因此将于 2026 年 TAO 手术完成后上市。一般来说，有关 HDM AIT 长期有效性的临床试验数据很少。我们在一项回顾性观察队列研究中评估了真实世界数据 (RWD)，该研究基于纵向理赔数据库，其中包括 60% 的德国法定医疗处方，以显示其中一种产品在日常生活中的长期有效性。该分析的目的是按照国际 AIT 指南的要求，对螨 AIT 的有效性进行每个产品的分析。